Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Paratek Pharmaceuticals Inc's Business Segments
Paratek Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 31
Regions Reported
-
Paratek Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Product84.6%
- Government Contract Grant Revenue7%
- Government Contract Service Revenue6.4%
- Collaboration and Royalty Revenue1.9%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 25 | 84.6% |
| Government Contract Grant Revenue | $ 2 | 7% |
| Government Contract Service Revenue | $ 2 | 6.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Paratek Pharmaceuticals Inc dataset.
Description of Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc is a US-based biopharmaceutical company that develops innovative therapies for the treatment of infectious diseases and other serious conditions. The company was founded in 1996 with a focus on developing antibiotics to address the growing problem of antibiotic-resistant bacteria.
The company's lead product is NUZYRA, a once-daily oral and intravenous antibiotic that is approved for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is unique in that it is effective against a wide range of bacteria, including those that are resistant to other antibiotics, such as MRSA.
In addition to NUZYRA, Paratek is also developing a second antibiotic, SEYSARA, for the treatment of acne vulgaris. SEYSARA is a once-daily oral antibiotic that targets a specific type of bacteria that is commonly associated with acne.
Paratek has a strong pipeline of additional antibiotics in development, including drugs targeting gram-negative bacteria, which are notoriously difficult to treat. The company's approach to drug development is focused on using innovative technologies and approaches to discover and develop drugs that are effective against drug-resistant bacteria.
Paratek has partnerships and collaborations with a number of academic and commercial organizations, including the US Department of Defense, which is funding the development of a new class of antibiotics for use in biodefense.
The company is headquartered in Boston, Massachusetts, and has additional offices in King of Prussia, Pennsylvania, and Zug, Switzerland. Paratek has a workforce of approximately 160 employees.
Overall, Paratek Pharmaceuticals is a pioneering biopharmaceutical company that is committed to developing innovative therapies for the treatment of infectious diseases and other serious conditions. With a strong pipeline of antibiotics in development and a focus on using cutting-edge technologies and approaches to drug discovery, Paratek is poised to make a significant impact on the field of antibiotic development and change the way we treat drug-resistant infections.
The company's lead product is NUZYRA, a once-daily oral and intravenous antibiotic that is approved for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is unique in that it is effective against a wide range of bacteria, including those that are resistant to other antibiotics, such as MRSA.
In addition to NUZYRA, Paratek is also developing a second antibiotic, SEYSARA, for the treatment of acne vulgaris. SEYSARA is a once-daily oral antibiotic that targets a specific type of bacteria that is commonly associated with acne.
Paratek has a strong pipeline of additional antibiotics in development, including drugs targeting gram-negative bacteria, which are notoriously difficult to treat. The company's approach to drug development is focused on using innovative technologies and approaches to discover and develop drugs that are effective against drug-resistant bacteria.
Paratek has partnerships and collaborations with a number of academic and commercial organizations, including the US Department of Defense, which is funding the development of a new class of antibiotics for use in biodefense.
The company is headquartered in Boston, Massachusetts, and has additional offices in King of Prussia, Pennsylvania, and Zug, Switzerland. Paratek has a workforce of approximately 160 employees.
Overall, Paratek Pharmaceuticals is a pioneering biopharmaceutical company that is committed to developing innovative therapies for the treatment of infectious diseases and other serious conditions. With a strong pipeline of antibiotics in development and a focus on using cutting-edge technologies and approaches to drug discovery, Paratek is poised to make a significant impact on the field of antibiotic development and change the way we treat drug-resistant infections.
Paratek Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative therapies targeting life-threatening infectious diseases and other serious medical conditions. The company has established itself as a leader in addressing critical therapeutic needs through its rich and varied pipeline, which encompasses three primary segments: antibiotics, vaccines, and anti-parasitic agents.
Antibiotics
Parateks antibiotics segment prominently features a range of therapies aimed at combatting serious bacterial infections, particularly those caused by difficult-to-treat strains, including multidrug-resistant organisms. The antibiotics developed by Paratek are designed to provide effective treatment options for both gram-positive and gram-negative bacterial infections.
- Nuzyra™ (Omadacycline): Parateks flagship antibiotic is Nuzyra, a once-daily formulation available in both intravenous and oral forms. It has received FDA approval for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Nuzyra acts by inhibiting bacterial protein synthesis, making it effective against a variety of resistant bacteria.
- Sarecycline (SEYSARA®): Although primarily marketed for the treatment of acne vulgaris, sarecyclines mechanism of action as a narrow-spectrum antibiotic means it also presents potential as an option for addressing other dermatological infections and conditions.
- Pipeline Innovations: Paratek is continuously engaged in research and development of new antibiotics. Several novel candidates are in various stages of preclinical and clinical development, targeting specific resistant bacteria and enhancing the current therapeutic landscape.
Vaccines
In addition to its antibiotic offerings, Paratek is investing in the development of vaccines that are crucial for preventive healthcare against certain infectious diseases.
- Lead Vaccine Product: Paratek is advancing a vaccine targeting Bacillus anthracis, the pathogen responsible for anthrax. The vaccine, along with a combination of omadacycline and rifamycin, is designed for both prophylactic use and in response to potential outbreaks. This dual approach aims to provide robust immunity from a serious threat, especially in high-risk populations.
- Broader Vaccine Targets: The vaccine segment also explores development options for other serious infectious diseases, including plague and tularemia, focusing on creating vaccines that offer long-lasting protection in the face of bioterrorism and natural outbreaks.
Anti-Parasitic Agents
Parateks commitment to addressing infectious diseases extends to the development of anti-parasitic agents, targeting infections that pose significant public health challenges, such as malaria and leishmaniasis.
- PTK-373: The lead candidate in this segment is PTK-373, which is currently in preclinical development. This agent targets the Plasmodium falciparum enzyme, shikimate kinase, essential for the survival of malaria parasites. By inhibiting this enzyme, PTK-373 has the potential to disrupt the life cycle of the parasites and offer a new therapeutic avenue for malaria treatment.
- Research and Development: Paratek’s anti-parasitic pipeline includes innovations aimed at both preventing and treating parasitic infections, reflecting a holistic approach to infectious disease management.
Conclusion
Paratek Pharmaceuticals Inc. stands out with its diverse and innovative array of products and services designed to combat serious infectious diseases. Through its antibiotic therapies, advanced vaccine candidates, and promising anti-parasitic agents, Paratek is positioned to play a vital role in tackling unmet medical needs, ultimately aiming to save lives and improve outcomes for patients battling life-threatening infections. The company’s agile focus on both emerging infections and resistant strains underscores its commitment to advancing public health in an increasingly complex infectious disease landscape.
Antibiotics
Parateks antibiotics segment prominently features a range of therapies aimed at combatting serious bacterial infections, particularly those caused by difficult-to-treat strains, including multidrug-resistant organisms. The antibiotics developed by Paratek are designed to provide effective treatment options for both gram-positive and gram-negative bacterial infections.
- Nuzyra™ (Omadacycline): Parateks flagship antibiotic is Nuzyra, a once-daily formulation available in both intravenous and oral forms. It has received FDA approval for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Nuzyra acts by inhibiting bacterial protein synthesis, making it effective against a variety of resistant bacteria.
- Sarecycline (SEYSARA®): Although primarily marketed for the treatment of acne vulgaris, sarecyclines mechanism of action as a narrow-spectrum antibiotic means it also presents potential as an option for addressing other dermatological infections and conditions.
- Pipeline Innovations: Paratek is continuously engaged in research and development of new antibiotics. Several novel candidates are in various stages of preclinical and clinical development, targeting specific resistant bacteria and enhancing the current therapeutic landscape.
Vaccines
In addition to its antibiotic offerings, Paratek is investing in the development of vaccines that are crucial for preventive healthcare against certain infectious diseases.
- Lead Vaccine Product: Paratek is advancing a vaccine targeting Bacillus anthracis, the pathogen responsible for anthrax. The vaccine, along with a combination of omadacycline and rifamycin, is designed for both prophylactic use and in response to potential outbreaks. This dual approach aims to provide robust immunity from a serious threat, especially in high-risk populations.
- Broader Vaccine Targets: The vaccine segment also explores development options for other serious infectious diseases, including plague and tularemia, focusing on creating vaccines that offer long-lasting protection in the face of bioterrorism and natural outbreaks.
Anti-Parasitic Agents
Parateks commitment to addressing infectious diseases extends to the development of anti-parasitic agents, targeting infections that pose significant public health challenges, such as malaria and leishmaniasis.
- PTK-373: The lead candidate in this segment is PTK-373, which is currently in preclinical development. This agent targets the Plasmodium falciparum enzyme, shikimate kinase, essential for the survival of malaria parasites. By inhibiting this enzyme, PTK-373 has the potential to disrupt the life cycle of the parasites and offer a new therapeutic avenue for malaria treatment.
- Research and Development: Paratek’s anti-parasitic pipeline includes innovations aimed at both preventing and treating parasitic infections, reflecting a holistic approach to infectious disease management.
Conclusion
Paratek Pharmaceuticals Inc. stands out with its diverse and innovative array of products and services designed to combat serious infectious diseases. Through its antibiotic therapies, advanced vaccine candidates, and promising anti-parasitic agents, Paratek is positioned to play a vital role in tackling unmet medical needs, ultimately aiming to save lives and improve outcomes for patients battling life-threatening infections. The company’s agile focus on both emerging infections and resistant strains underscores its commitment to advancing public health in an increasingly complex infectious disease landscape.